The Clinical Effect of TACE Combined with Lenvatinib in Patients with Mid-late Stage Liver Cancer and the Effect of Serum Tumor Markers
Objective To analyze the effect of combined application of transcatheter arterial chemoembolization(TACE)and lenvatinib in mid-late stage liver cancer.Methods A total of 94 patients with mid-late stage liver cancer admitted to Shouguang People's Hospital from March 2020 to March 2023 were conveniently selected as the research objects.According to different treatment methods,they were divided into control group(47 cases)and observation group(47 cases).The control group was treated with TACE,and the observation group was treated with TACE com-bined with lenvatinib.Both groups were followed up for 1 year.The clinical remission,tumor markers and vascular growth factor levels and prognosis were compared between the two groups.Results The objective remission rate of the observation group was 74.47%(35/47),which was higher than 53.19%(25/47)of the control group,and the difference was statistically significant(χ2=4.608,P<0.05).After 2 months of treatment,the levels of Ki-67 antigen and proliferat-ing cell nuclear antigen in the observation group were(18.52±7.11)pg/mL and(357.23±23.35)pg/mL,respectively,which were lower than those in the control group(24.38±8.31)pg/mL and(392.06±26.18)pg/mL,the differences were statistically significant(t=3.617,6.701,both P<0.05).After 2 months of treatment,the levels of platelet-derived growth factor and basic fibroblast growth factor in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).The total survival time and disease progression time of the observation group were longer than those of the control group,and the differences were statistically significant(both P<0.05).Conclusion The combination of TACE and lenvatinib can reduce the levels of tumor markers such as Ki-67 antigen and vascular growth factor in patients with mid-late stage liver cancer,which is beneficial to tumor con-trol and prolong survival.
NETL
NSTL
万方数据
